透明质酸酶对外伤性玻璃体积血转归影响的实验研究
|
摘要
目的:通过建立外伤性玻璃体积血模型,探讨透明质酸酶对兔眼外伤性玻璃体积血转归的影响,以及诱导完全性玻璃体后脱离的可能性,为玻璃体切除术易于清除积血玻璃体提供实验依据。
方法:28只(56眼)新西兰兔,右眼为实验眼,左眼为空白对照眼(28眼),右眼均造成外伤性玻璃体积血模型,1天后随机分为实验组和阳性对照组,每组14只(14眼)。实验组玻璃体腔注射透明质酸酶20IU(0.1ml),阳性对照组玻璃体腔注射BSS(0.1ml)。给药后分别于1天,3天,7天,14天,21天,28天测量眼压,行裂隙灯检查、直接检眼镜和裂隙灯眼底照相。其后每组随机抽取2只实验兔行眼球摘除,抽取玻璃体液测定玻璃体液bFGF的含量,取眼球壁组织做病理学检查和扫描电镜检查。
结果:(1)实验组和阳性对照组的玻璃体混浊分级在给药后1天、3天、7天各组之间差异无统计学意义(P>0.05),给药14天后实验组的玻璃体混浊严重程度显著低于阳性对照组,各组之间差异有统计学意义(P<0.05)。(2)眼压在给药前6小时实验组、阳性对照组和正常眼压组间比较差异无统计学意义(P>0.05)。给药后1天和给药后3天实验组兔眼眼压和正常兔眼压比较差异有统计学意义(P<0.05),和阳性对照组比较差异有统计学意义(P<0.05)。给药后7天,14天,21天和28天实验组及阳性对照组眼压与正常眼压相比及组间比较差异无统计学意义(P>0.05)。(3)实验组和阳性对照组玻璃体中bFGF的浓度随着时间推移均增高,但阳性对照组高幅度较实验组大,到给药14天时,阳性对照组bFGF的浓度浓度达到了1.24 pg/ml,而实验组bFGF的浓度浓度为0.62 pg/ml,空白组给药后1-28天bFGF的浓度为0.21～0.24 pg/ml,变化不大。(4)增生膜成纤维细胞的数量在给药后7～28天,实验组增生膜截面成纤维细胞数量小于阳性对照组,差异有统计学意义(P<0.05)。(5)组织病理学检查实验组和阳性对照组视网膜均出现了水肿和神经节细胞空泡样变、内界膜增厚等病理改变,但实验组较阳性对照组形成增殖膜少(6)扫描电镜检出1-28天兔眼实验组和对照组可见部分玻璃体后皮质和视网膜内界膜连接紧密,无完全性玻璃体后脱离(PVD)发生。
结论:透明质酸酶20IU于兔眼玻璃体腔内注射对视网膜没有毒性作用,可加速外伤性玻璃体玻璃体积血的消散,进而延缓了PVR的形成和发展。可造成眼压一过性降低,但不能造成完全性PVD。
Objective: Through establishing the experimemental animol model of traumatic vitreous hemorrhage,investigate the effect of Hyaluronidase on traumatic vitreous hemorrhage's turnover ,and the possibility of induce complete posterior detachment of vitreous ,to offer experiment data of cut the hematocele vitreous body easily in vitrectomy.
Methods: There is twenty eight pigmented rabbits with fifty-six eyes. All the left eyes are blank control.All the right eyes were posed the model of traumatic vitreous hemorrhage,fourteen rabbits with fouteen eyes were choosed at random received Hyaluronidase 20IU/0.1ml injected in vitreous space, and the others were injected with equivalent dose of balanced solt as control after one day. All the rabbits were monitored by clinical examination ,intraocular pressure and eyeground photograph at one day,three days,seven days,fourteen days,twenty-one days and twenty eight days.Then two rabbits in each group was sacrified ,measure the basic fibroblast growth factor by draw off vitreous humor, Light microscopy and scan electron microscopy examination were performed for the histological changes of retina .
Result: (1) The grade of vitreous opacity were no obvious change in experimental group and positive control group at one day,three days,seven days, vitreous opacity of experimental group was lower than positive control group after fourteen days,there were significantly difference in two groups. (2)There were no obvious change of IOP in each groups at six hours before inject drug. There were significantly difference of IOP between experimental group and positive control group, blank control group at at one day,three days,seven days. There were no obvious change of IOP in each groups after seven days.(3) The density of bFGF were increase in experimental group and positive control group with the lapse of time,bue the positive control group riser than experimental group,at fourteen days The density of bFGFwere1.24 pg/ml in positive control group , it's only 0.62 pg/ml in experimental group, it's no obvious change in blank control group.(4) The amount of fibroblast on the hyperplastic membrane in experimental group not so many as positive control group,there were significantly difference in two groups after seven days.(5)There were retinal edema and balloon change of ganglion cell ,thickening of inner limiting membrane in Light microscopy between experimental group and positive control group; but the hyperplastic membrane in experimental group not fewer positive control group.(6) The part of posterior vitreous cortex and internal limiting membrance connection tight at one day to twenty eight days,no produce in complete posterior detachment of vitreous. Conclusion: No retinal toxicity of Hyaluronidase 20IU/0.1ml injected in rabbit's vitreous space, accelerate the disappear of vitreous hemorrhage,then delay the shape and the development of proliferative vitreous retinopathy.It can make intraocular pressure temporal degrade,bue can't result in complete posterior detachment of vitreous.
方法:28只(56眼)新西兰兔,右眼为实验眼,左眼为空白对照眼(28眼),右眼均造成外伤性玻璃体积血模型,1天后随机分为实验组和阳性对照组,每组14只(14眼)。实验组玻璃体腔注射透明质酸酶20IU(0.1ml),阳性对照组玻璃体腔注射BSS(0.1ml)。给药后分别于1天,3天,7天,14天,21天,28天测量眼压,行裂隙灯检查、直接检眼镜和裂隙灯眼底照相。其后每组随机抽取2只实验兔行眼球摘除,抽取玻璃体液测定玻璃体液bFGF的含量,取眼球壁组织做病理学检查和扫描电镜检查。
结果:(1)实验组和阳性对照组的玻璃体混浊分级在给药后1天、3天、7天各组之间差异无统计学意义(P>0.05),给药14天后实验组的玻璃体混浊严重程度显著低于阳性对照组,各组之间差异有统计学意义(P<0.05)。(2)眼压在给药前6小时实验组、阳性对照组和正常眼压组间比较差异无统计学意义(P>0.05)。给药后1天和给药后3天实验组兔眼眼压和正常兔眼压比较差异有统计学意义(P<0.05),和阳性对照组比较差异有统计学意义(P<0.05)。给药后7天,14天,21天和28天实验组及阳性对照组眼压与正常眼压相比及组间比较差异无统计学意义(P>0.05)。(3)实验组和阳性对照组玻璃体中bFGF的浓度随着时间推移均增高,但阳性对照组高幅度较实验组大,到给药14天时,阳性对照组bFGF的浓度浓度达到了1.24 pg/ml,而实验组bFGF的浓度浓度为0.62 pg/ml,空白组给药后1-28天bFGF的浓度为0.21～0.24 pg/ml,变化不大。(4)增生膜成纤维细胞的数量在给药后7～28天,实验组增生膜截面成纤维细胞数量小于阳性对照组,差异有统计学意义(P<0.05)。(5)组织病理学检查实验组和阳性对照组视网膜均出现了水肿和神经节细胞空泡样变、内界膜增厚等病理改变,但实验组较阳性对照组形成增殖膜少(6)扫描电镜检出1-28天兔眼实验组和对照组可见部分玻璃体后皮质和视网膜内界膜连接紧密,无完全性玻璃体后脱离(PVD)发生。
结论:透明质酸酶20IU于兔眼玻璃体腔内注射对视网膜没有毒性作用,可加速外伤性玻璃体玻璃体积血的消散,进而延缓了PVR的形成和发展。可造成眼压一过性降低,但不能造成完全性PVD。
Objective: Through establishing the experimemental animol model of traumatic vitreous hemorrhage,investigate the effect of Hyaluronidase on traumatic vitreous hemorrhage's turnover ,and the possibility of induce complete posterior detachment of vitreous ,to offer experiment data of cut the hematocele vitreous body easily in vitrectomy.
Methods: There is twenty eight pigmented rabbits with fifty-six eyes. All the left eyes are blank control.All the right eyes were posed the model of traumatic vitreous hemorrhage,fourteen rabbits with fouteen eyes were choosed at random received Hyaluronidase 20IU/0.1ml injected in vitreous space, and the others were injected with equivalent dose of balanced solt as control after one day. All the rabbits were monitored by clinical examination ,intraocular pressure and eyeground photograph at one day,three days,seven days,fourteen days,twenty-one days and twenty eight days.Then two rabbits in each group was sacrified ,measure the basic fibroblast growth factor by draw off vitreous humor, Light microscopy and scan electron microscopy examination were performed for the histological changes of retina .
Result: (1) The grade of vitreous opacity were no obvious change in experimental group and positive control group at one day,three days,seven days, vitreous opacity of experimental group was lower than positive control group after fourteen days,there were significantly difference in two groups. (2)There were no obvious change of IOP in each groups at six hours before inject drug. There were significantly difference of IOP between experimental group and positive control group, blank control group at at one day,three days,seven days. There were no obvious change of IOP in each groups after seven days.(3) The density of bFGF were increase in experimental group and positive control group with the lapse of time,bue the positive control group riser than experimental group,at fourteen days The density of bFGFwere1.24 pg/ml in positive control group , it's only 0.62 pg/ml in experimental group, it's no obvious change in blank control group.(4) The amount of fibroblast on the hyperplastic membrane in experimental group not so many as positive control group,there were significantly difference in two groups after seven days.(5)There were retinal edema and balloon change of ganglion cell ,thickening of inner limiting membrane in Light microscopy between experimental group and positive control group; but the hyperplastic membrane in experimental group not fewer positive control group.(6) The part of posterior vitreous cortex and internal limiting membrance connection tight at one day to twenty eight days,no produce in complete posterior detachment of vitreous. Conclusion: No retinal toxicity of Hyaluronidase 20IU/0.1ml injected in rabbit's vitreous space, accelerate the disappear of vitreous hemorrhage,then delay the shape and the development of proliferative vitreous retinopathy.It can make intraocular pressure temporal degrade,bue can't result in complete posterior detachment of vitreous.
引文
[1] 李凤鸣,主编,眼科全书,北京,人民出版社,1996,2417-2422
[2] 闻祥根,汪振芳.玻璃体切除治疗外伤性严重玻璃体积血的研究.眼外伤职业病杂志,2001,23(2):126-127
[3] Kuppermann BD,Thomas EL, de Smet MD.et al. Pooled efficacy results from two multina- tional randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol. 2005 ,140(4):573-584.
[4] 程毅力, 彭宏宇,张莉.安妥碘与透明质酸酶球后注射治疗挫伤性玻璃体积血, 眼外伤职业眼病杂志 ,2002,6(24):675-676
[5] Forreter JV,Edger W,et al.Enhancement of vityius clotysis by urokinase:made of action .Exp Eye Res,1982,34:8951-8954
[6] Russell SR, Shepherd JD, Hageman GS. Distribution of glycoconjugates in the human retinal internal limiting membrane.Invest Ophthalmol Vis Sci, 1991, 32: 1986-1995
[7] Forreter JV,et al.the pathology of vitreous hemorrhage.Arch Ophthal,1978,96(4):703-710
[8] Forreter JV,et al.the pathology of vitreous hemorrhage.Arch Ophthal,1979,97(12):2368-2374
[9] Horven I,Radioautographic study of the erythrocyte phagocyting cellsin the rabbit eye.Acta ophthal,1964,42:800-802
[10] Greer DF,et al.A study of stimulated vitreous hemorrhage using labeled blood.Arch Ophthal,1968,79:755-757
[11] 骆荣江,周国筠.玻璃体积血的药物治疗及其作用机理.国外医学,眼科学分册,1991(4):156-157
[12] 石一宁,惠延年,王文勇,等.巨噬细胞诱导的增殖性玻璃体视网膜病变内的炎性因子.临床眼科杂志,1998:6(3):166-168
[13] Hui YN , Liang HC , Cai YS , et al1 Corticosteroids and daunomycin in the prevention experimental proliferative vitreore tionpathy induced by macrophages . Graefe’s Arch ClinExp Ophthalmol ,1993, 231 : 109-141
[14] 姜彩辉, 张卯年. 实验性外伤性增生性玻璃体视网膜病变动物模型的改进 眼科研究. 2003,21(6):579-581
[15] Cleary PE ,Ryan SJ . Experimental posterior penetrating eye injury in the rabbitΙ: method of production and natural history. Br J Ophthalmol ,1979,63 (2):306-309
[16] amule scu MA, Chen Y, He S , et al. Trans form in growth factor beta-ind ucedm yofib rob last icd ifferent iation of humanret in al pigment epithe lia lcells : regu lation by extracell ularma trix proteins and heptocyte growth factor . Exp Eye Res 2006; 83 (1) : 212-222.
[17] Gottlieb JL ,Antiszyk AN,Hatchell DL, et al . The safety of intravitreal hyaluronidase :a clinical and histological study . Invest Ophthalmol Vis Sci ,1990 ,31(11) :234-235
[18] Harooni M. Efficacy and safety of exzymatic posterior vitreous detachment by intravitreal injection of hyaluronidase . Retina ,1998 ,18(1) :162-164
[19] 刘雪霞,吴海洋, 陶海.纤溶酶和透明质酸酶在诱导猪玻璃体后脱离中对眼前部组织的影响.眼科新进展.2007,27(9):653-657
[20] Kuppermann BD, Thomas EL ,de Smet MD,et al.Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol. 2005 Oct;140(4):585-597.
[21] Kaplan P,Doval M,Majerova.et al.Iron-induced lipid peroxidation and protein modification by stobadine .Int J Biochem Cell Biol.2000,32:539-542
[22] 符晨雅 , 彭群 , 荆霄芸,等 .t-PA 治疗玻璃体积血的实验研究 . 中华眼底病杂志.1995,11:257-259
[23] 王莉菲,马景学,刘建宗,等.兔眼玻璃体视网膜交界面酶溶解分离研究。中华眼科杂志.2004,40(7):459-464
[24] LLashkari K,Rahimi N,Kazlauskas A,et al.Hepatocyte growth factor receptor in human RPE cells:implications in proliferative vitreoretinopathy.Invest Ophthalmol Vis Sci, 1999,40(1):149-156
[25] 管怀进,龚启荣主编,现代基础眼科学.人民军医出版社.1998,533
[26] Cassidy L ,Barry P, Shaw C,et al. Platelet derived growth factorand fibroblast growth factor basic levels in the vitreous of patientswith vitreoretinal disorders . Br J Ophthalmol ,1998 ,82(2):181-185
[27] Kon C H,Occleston N L, Aylward GW,et al. Expression ofvitreous cytokines in proliferative vitreoretinopathy . InvestOphthalmol Vis Sci 1999 ,40(3):705-712.
[28] Amin RH,Frank RN,Kennedy A,et al.Vasculur endothelial growth factor is present in glial cells often reting and present nerve of human subjects with nonproliferative diabetic retinepathy. [J] Invest Ophthalmol Vis Sci ,1997 ,38 :36-47
[29] 付小兵,沈祖,陈玉林,等.碱性成纤维细胞生长因子与创面修复-1024例多中心对照临床实验结果.中国修复重建外科杂志,1998,14:33-34
[30] Ripandelli G,Parisi V,Friberg TR,et al.Retinal detachment associated with macular hole in high myopia:using the anatomy to optimize the surgical approach. Ophthalmology.2004; 111(4): 726-731
[31] Nowosielska A,Robaszkiewcz J,Graczynska E,et al.The influence of spontaneous posterior vitreous detachment in resolution of diabetic macular edema in NIDDM.Klin Oczna.2003;105 (6):355-361
[32] Hikichi T,Masanori K,Yoshida A.Intravitreal injection of hyaluronidase cannot induce posterior vitreous detachment in the rabbit.Retina 2000;20:195-198
[33] Grierson I,Forrester JV.Vitreous haemorrhage and vitreal membranes. Trans Ophthalmol Soc U K.1980 4;100:140-150.
[34] 李顺意,梁宋平.透明质酸酶研究进展.国外医学分子生物学分册.1995,2(17):76-79 [35] 徐庆,周慧芳,罗敏.球后阻滞麻醉中透明质酸酶对眼内压及间接眶压的影响中国实用眼科杂志2004 ,22 (4):263-265
[35] 朱蓉嵘 管怀进.透明质酸酶在眼科手术中的应用研究进展.国外医学眼科学分册. 2001,25(4):212-216
[36] 余顺,麻从,乔健夫等.透明质酸酶对眼压影响的实验研究.眼科新进展.1994,14(1):1-4
[37] Zimmerman LE.Demonstration of hyaluronidase-sensitive acid mucopolysaccharide in trabecula and iris in routine paraffin sections of adult human eyes; a preliminary report. Am J Ophthalmol.1957 Jul;44(1):1-4
[38] Rankova CB,Siarov NP,Petkova N.Application of hyaluronidase after unsuccessful trabeculectomy. Doc Ophthalmol. 1992;80(4):381-383.
[39] Grierson I,Lee WR,Abraham S.A light microscopic study of the effects of testicular hyaluronidase on the outflow system of a baboon (Papio cynocephalus). Invest Ophthalmol Vis Sci.1979 18(4):356-360
1 Gadkari SS, Kamdar PA, Jehangir RP. Pars plana vitrectomy in vitreous hemorrhage due to Eales' disease[J]. Indian J Ophthalmol, 1992, 40:35-37
2 惠延年. 眼科学[M]. 第 6 版. 北京:人民卫生出版社, 2004. 173
3 Sanders MD, Graham EM. Retinal vasculitis[J]. Postgrad Med J, 1988, 64:488-496
4 Palmer HE, Stanford MR, Sanders MD, et al. Visual outcome of patients with idiopathic ischaemic and non-ischaemic retinal vasculitis[J]. Eye, 1996, 10:343-348
5 Walton RC, Ashmore ED. Retinal vasculitis[J]. Curr Opin Ophthalmol, 2003, 14:413 -419
6 Rahi AH, Tabbara KF. Retinal vasculitis: pathogenesis and laboratory investigations[J]. Int Ophthalmol Clin, 1995, 35:93-105
7 Stanford MR, Verity DH. Diagnostic and therapeutic approach to patients with retinal vasculitis[J]. Int Ophthalmol Clin, 2000, 40:69-83
8 Ermakova NA, Balishanskaia TI. Clinical picture of isolated retinal vasculitis[J]. Vestn Oftalmol, 2000, 116:16-20
9 Saxena S, Kumar D. A new staging system for idiopathic retinal periphlebitis[J]. Eur J Ophthalmol, 2004, 14:236-239
10 Madhavan HN, Therese KL, Gunisha P, et al. Polymerase chain reaction for detection of Mycobacterium tuberculosis in epiretinal membrane in Eales disease[J]. Invest Ophthalmol Vis Sci, 2000, 41:822-825
11 Biswas J, Therese L, Madhavan HN. Use of polymerase chain reaction in detection of mycobacterium tuberculosis complex DNA from vitreous sample of Eales disease[J]. Br J Ophthaloqicum, 1999, 83:994
12 姚毅, 王兵, 马志中. 高粘血症视网膜血管炎致玻璃体积血二例[J]. 中华眼底病杂志, 2001, 17:319
13 Bertram B, Wolf S, Hof A. Rheologic findings in patients with Eales disease[J]. Klin Monatsbl Augenheilkd, 1989, 195:254-256
14Gallaqher MJ, Ooi KG, Thomas M, et al. ANCA associated pauci-immune retinal vasculitis[J]. Br J Ophthalmol, 2005, 89:608-611
15Isaq M, Karamat S, Niazi MK. HLA typing in patients of Eales’ disease[J]. J Coll Physicians Surg Pak, 2005, 15:288-290
16George RK, Chan CC, Whitcup SM, et al. Ocular immunopathology of Behcet's disease [J]. Surv Ophthalmol, 1997, 42:157-162
17Merle H, Donnio A, Gonin C, et al. Retinal vasculitis caused by adult T-cell leukemia/lymphoma[J]. Jpn J Ophthalmol, 2005, 49:41-45
18 Sandeep S, Dipak K, Hanna K, et al. Impaired anti-oxidant defence mechanism in central Eales disease[J]. Ann Ophthalmol, 2004, 36:29-31
19 Sandeep S, Prachi S, Dipak K, et al. Decreased platelet membrane fluidity in retinal periphlebitis in Eales’ disease[J]. Taylor Francis, 2006, 14:113-116
20 Rajesh M, Sulochana KN, Punitham R, et al. Involvement of oxidative and nitrosative stress in promoting retinal vasculitis in patients with Eales' disease[J]. Clin Biochem, 2003, 36:377-385
21 Fischer PA, Dominguez GN, Cuniberti LA, et al. Hyperhomocysteinemia induces renal hemodynamic dysfunction: Is nitric oxide involved[J]? J Am Soc Nephrol, 2003, 14: 653 -600
22 Becquet F, Courtois Y, Goureau O. Nitric oxide in the eye: multifaceted roles and diverse outcomes[J]. Surv Ophthalmol, 1997, 42:71-82
23 Perentes Y, Chan CC, Bovey E, et al. Massive vascular endothelium growth factor (VEGF) expression in Eales' disease[J]. Klin Monatsbl Augenheilkd, 2002, 219:311-314
24 万新顺, 刘瑞芳, 刘向玲, 等. Eales’病患者眼内液血管内皮生长因子检测及意义[J].眼科研究, 2003, 21:318-320
25 刘家琦. 实用眼科学[M]. (第 2 版). 北京:人民卫生出版社, 2000. 468
26Saxena S, Kumar D. The Topographic distribution of retinal neovascularization in Eales' disease[J]. Ann Ophthalmol, 2005, 37:273-275
27 Ermakova NA. Conservative therapy of isolated retinal vasculitis[J]. Vestn Oftalmol, 2001,
117:36-38
28 Fardeau C. Interferon and retinal vasculitis[J]. J Fr Ophthalmol, 2006, 29:392-397
29 Williamson TH, O'Donnell A. Intravitreal triamcinolone acetonide for cystoid macular edema in nonischemic central retinal vein occlusion[J]. Am J Ophthalmol, 2005, 139: 860-866
30Isaq M,Feroze AH, Shahid M, et al. Intravitreous steroids may facilitate treatment of Eales’ disease(idiopathic retinal vasculitis):an interventreal case series[J]. Eye, 2007, 21:1403-1405
31 镡旭民. 巨细胞病毒性视网膜炎的药物治疗[J]. 国外医学·药学分册, 2000, 27: 105-107
32Robinson GS, Pierce EA, Rook SL, et al. Oligodeoxynucletides inhibit retinal neovascularization in amurine model of proliferative retinopathy[J]. Med Sci, 1995, 93:4851-4856
33Iriyama A, Chen YN, Tamaki Y, et al. Effect of the anti-VEGF antibody on the retinal ganglion cells of rat[J]. Br J Ophthalmol, 2007, 9:1230-1233
34 梁小玲, 金称进, 梁凌毅. 应用激光抑制视网膜血管炎新生血管发生的临床研究[J]. 新医学, 1998, 29:471-473
35Isaq M, Niazi MK. Usefulness of laser photocoagulation in managing asymptomatic eyes of Eales’ disease[J]. J Ayub Med Coll Abbottabad, 2002, 14:22-25
36Dehqhan MH, Ahmadich H, Soheilian M, et al. Therapeutic effects of laser photocoagulation and/or vitrectomy in Eales’disease[J]. Eur J Ophthalmol, 2005, 15: 379-383
[2] 闻祥根,汪振芳.玻璃体切除治疗外伤性严重玻璃体积血的研究.眼外伤职业病杂志,2001,23(2):126-127
[3] Kuppermann BD,Thomas EL, de Smet MD.et al. Pooled efficacy results from two multina- tional randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol. 2005 ,140(4):573-584.
[4] 程毅力, 彭宏宇,张莉.安妥碘与透明质酸酶球后注射治疗挫伤性玻璃体积血, 眼外伤职业眼病杂志 ,2002,6(24):675-676
[5] Forreter JV,Edger W,et al.Enhancement of vityius clotysis by urokinase:made of action .Exp Eye Res,1982,34:8951-8954
[6] Russell SR, Shepherd JD, Hageman GS. Distribution of glycoconjugates in the human retinal internal limiting membrane.Invest Ophthalmol Vis Sci, 1991, 32: 1986-1995
[7] Forreter JV,et al.the pathology of vitreous hemorrhage.Arch Ophthal,1978,96(4):703-710
[8] Forreter JV,et al.the pathology of vitreous hemorrhage.Arch Ophthal,1979,97(12):2368-2374
[9] Horven I,Radioautographic study of the erythrocyte phagocyting cellsin the rabbit eye.Acta ophthal,1964,42:800-802
[10] Greer DF,et al.A study of stimulated vitreous hemorrhage using labeled blood.Arch Ophthal,1968,79:755-757
[11] 骆荣江,周国筠.玻璃体积血的药物治疗及其作用机理.国外医学,眼科学分册,1991(4):156-157
[12] 石一宁,惠延年,王文勇,等.巨噬细胞诱导的增殖性玻璃体视网膜病变内的炎性因子.临床眼科杂志,1998:6(3):166-168
[13] Hui YN , Liang HC , Cai YS , et al1 Corticosteroids and daunomycin in the prevention experimental proliferative vitreore tionpathy induced by macrophages . Graefe’s Arch ClinExp Ophthalmol ,1993, 231 : 109-141
[14] 姜彩辉, 张卯年. 实验性外伤性增生性玻璃体视网膜病变动物模型的改进 眼科研究. 2003,21(6):579-581
[15] Cleary PE ,Ryan SJ . Experimental posterior penetrating eye injury in the rabbitΙ: method of production and natural history. Br J Ophthalmol ,1979,63 (2):306-309
[16] amule scu MA, Chen Y, He S , et al. Trans form in growth factor beta-ind ucedm yofib rob last icd ifferent iation of humanret in al pigment epithe lia lcells : regu lation by extracell ularma trix proteins and heptocyte growth factor . Exp Eye Res 2006; 83 (1) : 212-222.
[17] Gottlieb JL ,Antiszyk AN,Hatchell DL, et al . The safety of intravitreal hyaluronidase :a clinical and histological study . Invest Ophthalmol Vis Sci ,1990 ,31(11) :234-235
[18] Harooni M. Efficacy and safety of exzymatic posterior vitreous detachment by intravitreal injection of hyaluronidase . Retina ,1998 ,18(1) :162-164
[19] 刘雪霞,吴海洋, 陶海.纤溶酶和透明质酸酶在诱导猪玻璃体后脱离中对眼前部组织的影响.眼科新进展.2007,27(9):653-657
[20] Kuppermann BD, Thomas EL ,de Smet MD,et al.Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol. 2005 Oct;140(4):585-597.
[21] Kaplan P,Doval M,Majerova.et al.Iron-induced lipid peroxidation and protein modification by stobadine .Int J Biochem Cell Biol.2000,32:539-542
[22] 符晨雅 , 彭群 , 荆霄芸,等 .t-PA 治疗玻璃体积血的实验研究 . 中华眼底病杂志.1995,11:257-259
[23] 王莉菲,马景学,刘建宗,等.兔眼玻璃体视网膜交界面酶溶解分离研究。中华眼科杂志.2004,40(7):459-464
[24] LLashkari K,Rahimi N,Kazlauskas A,et al.Hepatocyte growth factor receptor in human RPE cells:implications in proliferative vitreoretinopathy.Invest Ophthalmol Vis Sci, 1999,40(1):149-156
[25] 管怀进,龚启荣主编,现代基础眼科学.人民军医出版社.1998,533
[26] Cassidy L ,Barry P, Shaw C,et al. Platelet derived growth factorand fibroblast growth factor basic levels in the vitreous of patientswith vitreoretinal disorders . Br J Ophthalmol ,1998 ,82(2):181-185
[27] Kon C H,Occleston N L, Aylward GW,et al. Expression ofvitreous cytokines in proliferative vitreoretinopathy . InvestOphthalmol Vis Sci 1999 ,40(3):705-712.
[28] Amin RH,Frank RN,Kennedy A,et al.Vasculur endothelial growth factor is present in glial cells often reting and present nerve of human subjects with nonproliferative diabetic retinepathy. [J] Invest Ophthalmol Vis Sci ,1997 ,38 :36-47
[29] 付小兵,沈祖,陈玉林,等.碱性成纤维细胞生长因子与创面修复-1024例多中心对照临床实验结果.中国修复重建外科杂志,1998,14:33-34
[30] Ripandelli G,Parisi V,Friberg TR,et al.Retinal detachment associated with macular hole in high myopia:using the anatomy to optimize the surgical approach. Ophthalmology.2004; 111(4): 726-731
[31] Nowosielska A,Robaszkiewcz J,Graczynska E,et al.The influence of spontaneous posterior vitreous detachment in resolution of diabetic macular edema in NIDDM.Klin Oczna.2003;105 (6):355-361
[32] Hikichi T,Masanori K,Yoshida A.Intravitreal injection of hyaluronidase cannot induce posterior vitreous detachment in the rabbit.Retina 2000;20:195-198
[33] Grierson I,Forrester JV.Vitreous haemorrhage and vitreal membranes. Trans Ophthalmol Soc U K.1980 4;100:140-150.
[34] 李顺意,梁宋平.透明质酸酶研究进展.国外医学分子生物学分册.1995,2(17):76-79 [35] 徐庆,周慧芳,罗敏.球后阻滞麻醉中透明质酸酶对眼内压及间接眶压的影响中国实用眼科杂志2004 ,22 (4):263-265
[35] 朱蓉嵘 管怀进.透明质酸酶在眼科手术中的应用研究进展.国外医学眼科学分册. 2001,25(4):212-216
[36] 余顺,麻从,乔健夫等.透明质酸酶对眼压影响的实验研究.眼科新进展.1994,14(1):1-4
[37] Zimmerman LE.Demonstration of hyaluronidase-sensitive acid mucopolysaccharide in trabecula and iris in routine paraffin sections of adult human eyes; a preliminary report. Am J Ophthalmol.1957 Jul;44(1):1-4
[38] Rankova CB,Siarov NP,Petkova N.Application of hyaluronidase after unsuccessful trabeculectomy. Doc Ophthalmol. 1992;80(4):381-383.
[39] Grierson I,Lee WR,Abraham S.A light microscopic study of the effects of testicular hyaluronidase on the outflow system of a baboon (Papio cynocephalus). Invest Ophthalmol Vis Sci.1979 18(4):356-360
1 Gadkari SS, Kamdar PA, Jehangir RP. Pars plana vitrectomy in vitreous hemorrhage due to Eales' disease[J]. Indian J Ophthalmol, 1992, 40:35-37
2 惠延年. 眼科学[M]. 第 6 版. 北京:人民卫生出版社, 2004. 173
3 Sanders MD, Graham EM. Retinal vasculitis[J]. Postgrad Med J, 1988, 64:488-496
4 Palmer HE, Stanford MR, Sanders MD, et al. Visual outcome of patients with idiopathic ischaemic and non-ischaemic retinal vasculitis[J]. Eye, 1996, 10:343-348
5 Walton RC, Ashmore ED. Retinal vasculitis[J]. Curr Opin Ophthalmol, 2003, 14:413 -419
6 Rahi AH, Tabbara KF. Retinal vasculitis: pathogenesis and laboratory investigations[J]. Int Ophthalmol Clin, 1995, 35:93-105
7 Stanford MR, Verity DH. Diagnostic and therapeutic approach to patients with retinal vasculitis[J]. Int Ophthalmol Clin, 2000, 40:69-83
8 Ermakova NA, Balishanskaia TI. Clinical picture of isolated retinal vasculitis[J]. Vestn Oftalmol, 2000, 116:16-20
9 Saxena S, Kumar D. A new staging system for idiopathic retinal periphlebitis[J]. Eur J Ophthalmol, 2004, 14:236-239
10 Madhavan HN, Therese KL, Gunisha P, et al. Polymerase chain reaction for detection of Mycobacterium tuberculosis in epiretinal membrane in Eales disease[J]. Invest Ophthalmol Vis Sci, 2000, 41:822-825
11 Biswas J, Therese L, Madhavan HN. Use of polymerase chain reaction in detection of mycobacterium tuberculosis complex DNA from vitreous sample of Eales disease[J]. Br J Ophthaloqicum, 1999, 83:994
12 姚毅, 王兵, 马志中. 高粘血症视网膜血管炎致玻璃体积血二例[J]. 中华眼底病杂志, 2001, 17:319
13 Bertram B, Wolf S, Hof A. Rheologic findings in patients with Eales disease[J]. Klin Monatsbl Augenheilkd, 1989, 195:254-256
14Gallaqher MJ, Ooi KG, Thomas M, et al. ANCA associated pauci-immune retinal vasculitis[J]. Br J Ophthalmol, 2005, 89:608-611
15Isaq M, Karamat S, Niazi MK. HLA typing in patients of Eales’ disease[J]. J Coll Physicians Surg Pak, 2005, 15:288-290
16George RK, Chan CC, Whitcup SM, et al. Ocular immunopathology of Behcet's disease [J]. Surv Ophthalmol, 1997, 42:157-162
17Merle H, Donnio A, Gonin C, et al. Retinal vasculitis caused by adult T-cell leukemia/lymphoma[J]. Jpn J Ophthalmol, 2005, 49:41-45
18 Sandeep S, Dipak K, Hanna K, et al. Impaired anti-oxidant defence mechanism in central Eales disease[J]. Ann Ophthalmol, 2004, 36:29-31
19 Sandeep S, Prachi S, Dipak K, et al. Decreased platelet membrane fluidity in retinal periphlebitis in Eales’ disease[J]. Taylor Francis, 2006, 14:113-116
20 Rajesh M, Sulochana KN, Punitham R, et al. Involvement of oxidative and nitrosative stress in promoting retinal vasculitis in patients with Eales' disease[J]. Clin Biochem, 2003, 36:377-385
21 Fischer PA, Dominguez GN, Cuniberti LA, et al. Hyperhomocysteinemia induces renal hemodynamic dysfunction: Is nitric oxide involved[J]? J Am Soc Nephrol, 2003, 14: 653 -600
22 Becquet F, Courtois Y, Goureau O. Nitric oxide in the eye: multifaceted roles and diverse outcomes[J]. Surv Ophthalmol, 1997, 42:71-82
23 Perentes Y, Chan CC, Bovey E, et al. Massive vascular endothelium growth factor (VEGF) expression in Eales' disease[J]. Klin Monatsbl Augenheilkd, 2002, 219:311-314
24 万新顺, 刘瑞芳, 刘向玲, 等. Eales’病患者眼内液血管内皮生长因子检测及意义[J].眼科研究, 2003, 21:318-320
25 刘家琦. 实用眼科学[M]. (第 2 版). 北京:人民卫生出版社, 2000. 468
26Saxena S, Kumar D. The Topographic distribution of retinal neovascularization in Eales' disease[J]. Ann Ophthalmol, 2005, 37:273-275
27 Ermakova NA. Conservative therapy of isolated retinal vasculitis[J]. Vestn Oftalmol, 2001,
117:36-38
28 Fardeau C. Interferon and retinal vasculitis[J]. J Fr Ophthalmol, 2006, 29:392-397
29 Williamson TH, O'Donnell A. Intravitreal triamcinolone acetonide for cystoid macular edema in nonischemic central retinal vein occlusion[J]. Am J Ophthalmol, 2005, 139: 860-866
30Isaq M,Feroze AH, Shahid M, et al. Intravitreous steroids may facilitate treatment of Eales’ disease(idiopathic retinal vasculitis):an interventreal case series[J]. Eye, 2007, 21:1403-1405
31 镡旭民. 巨细胞病毒性视网膜炎的药物治疗[J]. 国外医学·药学分册, 2000, 27: 105-107
32Robinson GS, Pierce EA, Rook SL, et al. Oligodeoxynucletides inhibit retinal neovascularization in amurine model of proliferative retinopathy[J]. Med Sci, 1995, 93:4851-4856
33Iriyama A, Chen YN, Tamaki Y, et al. Effect of the anti-VEGF antibody on the retinal ganglion cells of rat[J]. Br J Ophthalmol, 2007, 9:1230-1233
34 梁小玲, 金称进, 梁凌毅. 应用激光抑制视网膜血管炎新生血管发生的临床研究[J]. 新医学, 1998, 29:471-473
35Isaq M, Niazi MK. Usefulness of laser photocoagulation in managing asymptomatic eyes of Eales’ disease[J]. J Ayub Med Coll Abbottabad, 2002, 14:22-25
36Dehqhan MH, Ahmadich H, Soheilian M, et al. Therapeutic effects of laser photocoagulation and/or vitrectomy in Eales’disease[J]. Eur J Ophthalmol, 2005, 15: 379-383